Related Experiment Videos
Novel mutations in the p16/CDKN2A binding region of the cyclin-dependent kinase-4 gene
1Department of Dermatology, Massachusetts General Hospital and Dana-Farber/Partner Cancer Care, Boston 02114, USA.
Abstract:
Mutations in genes that lie in the retinoblastoma pathway have been implicated in the pathogenesis of many tumor types. Two critical components that determine progression from G1 to S include p16/CDKN2A and CDK4. Alterations in p16/CDKN2A have been well documented in multiple cancers, including melanoma. However, changes in CDK4 are apparently more rare. Only two alterations, both at codon 24, have been identified in CDK4: an activating arginine-to-cysteine transition and a germ-line arginine-to-histidine substitution in one French kindred. In a survey of 20 neuroblastomas, 17 uncultured metastatic melanomas, 33 uncultured primary uveal melanomas, 8 colon cancer cell lines, and 20 primary colon cancer samples, we found no evidence of mutations in exon 2 of CDK4. From our cell lines derived from metastatic melanomas, we detected two alterations in the functionally critical exon 2 of CDK4: a lysine-to-glutamine transition at codon 22 and the arginine-to-histidine mutation at codon 24. These findings document several novel changes in the p16-binding region of CDK4.
Insights
This study investigated mutations in the CDK4 gene, crucial for cell cycle progression. Novel CDK4 alterations were found in metastatic melanomas, suggesting a role in cancer development.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- The retinoblastoma pathway is vital in cell cycle regulation and tumor suppression.
- Mutations in p16/CDKN2A are common in various cancers, including melanoma.
- Alterations in CDK4, a key cell cycle regulator, are considered rare.
Purpose of the Study:
- To investigate mutations in the CDK4 gene, specifically exon 2, in various cancer types.
- To identify novel alterations in CDK4 and their potential role in cancer pathogenesis.
Main Methods:
- Screening of CDK4 exon 2 for mutations in neuroblastomas, melanomas, and colon cancer samples and cell lines.
- Analysis of DNA from uncultured primary and metastatic tumors, as well as established cell lines.
Main Results:
- No mutations in CDK4 exon 2 were detected in neuroblastomas, uveal melanomas, or colon cancer samples.
- Two novel alterations in CDK4 exon 2 were identified in cell lines derived from metastatic melanomas: K22Q and R24H.
- These mutations affect the p16-binding region of CDK4.
Conclusions:
- The study identified novel mutations in the p16-binding region of CDK4.
- These findings expand the known spectrum of CDK4 alterations in cancer, particularly in metastatic melanoma.